Où docteurs et entreprises se rencontrent
Menu
Connexion

Vous avez déjà un compte ?

Nouvel utilisateur ?

Stage master 2 / ingénieur de recherche en Oncologie

ABG-94151 Stage master 2 / Ingénieur 6 mois 565
22/10/2020
Logo de
STIM CNRS ERL 7003
Poitiers Nouvelle Aquitaine France
  • Biologie
  • Santé, médecine humaine, vétérinaire
cancer, targeted therapies, resistance, melanoma.
02/11/2020

Établissement recruteur

Ce stage sera réalisé au sein du laboratoire STIM (CNRS ERL-7003). La recherche menée dans cette unité concerne l’étude de la signalisation cellulaire liée aux canaux et transporteurs ioniques transmembranaires dans les cancers et les cellules souches. Les projets sont menés en partenariat avec le CHU de Poitiers.

Description

CHARACTERIZATION AND VALIDATION OF NEW THERAPEUTIC TARGETS TO OVERCOME MELANOMA RESISTANCES TO TARGETED THERAPIES

 

Melanoma is a very aggressive form of skin cancer. It results from the malignant transformation of the pigmented cells of the skin, the melanocytes, following excessive sun exposure. Early detection allows to cure this disease by surgically removing the in-situ tumour. Unfortunately, for patients who present with an advanced and metastatic disease, the prognosis is still very poor. 60% of Melanoma patients bear driver mutations the BRAF gene that hyperactivate the MAPK pathway and make cells proliferate in an uncontrolled manner. Discovery of this genetic alteration has guided the clinical development of targeted therapies (i.e.BRAF and MEK inhibitors). Such MAPK pathway-targeting approaches have shown clear clinical benefits on patient’s survival. Yet, a significant portion of subjects initially do not respond. As for the others, the treatment works only for a limited time because tumor cells ultimately develop mechanisms of acquired drug resistance leading to relapse and death

 

Project Description:

Using a strategy based on a global and integrated analysis of both gene expression profiling and functional approaches, we have identified a new dysregulated pathway in dedifferentiated melanoma cells resistant to targeted therapies. 

During his/her internship, the selected candidate will have for mission to validate some of the identified targets in silicoin vitro and in vivo.

 

The selected candidate will be working in a dynamic environment and be trained to various techniques including, but not limited to: cell culture, transfection, lentiviral transduction, inducible gene downregulation, qPCR & Western-blotting, leading-edge microscopy approaches, cell-based assays and animal experimentation.

Profil

  • Bac+5 student (master 2 or engineer) with excellent academic record.
  • Strong interests for cell signaling challenges applied to cancer biomarker/therapeutic targets discovery.
  • Motivated team player with can-do attitude, initiative and innovative thinking and demonstrated organizational skills.
  • Excellent written and oral communication skills

  •  

Prise de fonction

04/01/2021
Partager via
Postuler
Fermer

Vous avez déjà un compte ?

Nouvel utilisateur ?

Besoin d'informations ?

Vous souhaitez recevoir une ou plusieurs lettres d’information de l’ABG. Chaque mois des actualités, des offres, des outils, un agenda…

Ils nous font confiance